Indianapolis, INNCT07816666Now EnrollingIRB Ready

Platinum-sensitive Relapsed Epithelial Ovarian Cancer Clinical Trial in Indianapolis, IN

Access cutting-edge platinum-sensitive relapsed epithelial ovarian cancer treatment through this phase 3 clinical trial at a research site in Indianapolis. Study-provided care at no cost to qualified participants.

Sponsored by AstraZeneca

Quick Self-Assessment

See if you qualify for this Indianapolis location

Preparing your pre-screening questions…

Expert Care in Indianapolis

Access platinum-sensitive relapsed epithelial ovarian cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related platinum-sensitive relapsed epithelial ovarian cancer treatment provided free

Apply for This Indianapolis Location

Check if you qualify for this platinum-sensitive relapsed epithelial ovarian cancer clinical trial in Indianapolis, IN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Indianapolis

    Convenient for IN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Indianapolis site if eligible
  4. 4Begin participation

About This Platinum-sensitive Relapsed Epithelial Ovarian Cancer Study in Indianapolis

The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (SoC) as maintenance treatment in participants with platinum-sensitive relapsed ovarian cancer (PSR OC)

Sponsor: AstraZeneca

Who Can Participate

Inclusion Criteria

Participants with confirmed histology of high-grade epithelial serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer.
Provision of an archival FFPE tumour sample
Participants who received at least one, and no more than 2 lines of prior systemic anticancer therapy.
Participants with radiologically confirmed disease relapse ≥ 6 months after their last platinum chemotherapy infusion in the previous line of treatment
Participants who received 4-6 cycles of PBC during the induction phase of their current line of treatment.
Participants assigned to bevacizumab must have received a minimum of 3 cycles of bevacizumab with 3 cycles of PBC prior to randomisation.
Participants with non-progressive disease upon completion of PBC in their current line of treatment.
Participants with documented BRCA mutation 1/2 must have received prior PARP inhibitor (unless ineligible due to contraindications, precautions, or intolerance).

Exclusion Criteria

Participants with tumours of non-epithelial origin, borderline tumours, clear cell OC, mucinous OC, carcinosarcoma, or low-grade epithelial tumours.
Participants with history of (non-infectious) ILD/pneumonitis that required steroids, or supplemental oxygen, or has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening
Participants with non-healing wound, active ulcer, or bone fracture (not applicable if not receiving bevacizumab)
Participants with evidence of active or ongoing bowel obstruction (not applicable if not receiving bevacizumab)
Participants with prior exposure to any FRα-targeted therapy, including MIRV, or any TOP1i Antibody-drug Conjugate (ADC)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Indianapolis?

Yes, this clinical trial (NCT07816666) has an active research site in Indianapolis, IN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Platinum-sensitive Relapsed Epithelial Ovarian Cancer Treatment Options in Indianapolis, IN

If you're searching for platinum-sensitive relapsed epithelial ovarian cancer treatment options in Indianapolis, IN, this clinical trial (NCT07816666) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Indianapolis research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced platinum-sensitive relapsed epithelial ovarian cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all platinum-sensitive relapsed epithelial ovarian cancer clinical trials near you to find additional studies recruiting in your area.

More Ovarian Cancer Trials in Indianapolis, IN

See all ovarian cancer clinical trials recruiting in Indianapolis — not just this study.

Browse Ovarian Cancer Trials in Indianapolis →

Browse More Trials by Condition

Ovarian Cancer TrialsAntiphospholipid Syndrome TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Indianapolis?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Indianapolis, IN